10-Q: bioAffinity Technologies Reports Q1 2025 Results: Revenue Declines Amid Strategic Shift, Focus on CyPath Lung

bioAffinity Technologies' Q1 2025 revenue decreased by 23% due to strategic actions, but CyPath Lung testing revenue increased significantly.

Summary

• bioAffinity Technologies reported a net loss of $2.7 million for the three months ended March 31, 2025, compared to a net loss of $2.0 million for the same period in 2024.
• Revenue decreased by approximately 23% to $1.9 million, primarily due to discontinuing certain unprofitable pathology services.
• CyPath Lung testing revenue increased by approximately 275% to $169,000, driven by an increase in total test results delivered.
• The company raised approximately $1.4 million in gross proceeds from equity transactions to fund operating activities.
• Operating expenses increased slightly to $4.5 million, with clinical development expenses rising significantly.
• The company has substantial doubt about its ability to continue as a going concern for the next 12 months.
• The company needs to raise further capital to support its future operations.

Sentiment

Score: 4

Explanation: The sentiment is slightly negative due to the increased net loss, decreased revenue, and going concern uncertainty, although there are positive signs in the growth of CyPath Lung and recent capital raises.

Positives

• CyPath Lung testing revenue increased significantly, indicating growing adoption of the diagnostic test.
• The company is taking strategic actions to improve financial performance and accelerate the commercial growth of CyPath Lung.
• The company successfully raised capital through equity transactions and a warrant inducement agreement.
• The company released CyPath Lung In Practice authored by Gordon Downie, MD, PhD, Director of the Titus Regional Hospital Lung Nodule Clinic and Interventional Pulmonology, in which he presented his experience and approach to using CyPath Lung in medical practice, including four case studies in which CyPath Lung proved clinically determinative.

Negatives

• Overall revenue decreased due to the discontinuation of certain pathology services.
• The company is experiencing significant net losses and negative cash flows.
• There is substantial doubt about the company's ability to continue as a going concern.
• The company's stockholders equity of approximately $1.4 million is below the Nasdaq required stockholders equity of $2.5 million.

Risks

• The company's business plan relies on obtaining additional capital, and failure to do so could require ceasing operations.
• The company may not succeed in generating sufficient income to achieve profitability.
• The company's failure to meet the continued listing requirements of The Nasdaq Capital Market could result in a de-listing of its Common Stock.
• The company's management collectively owns a substantial percentage of its Common Stock, which could prevent investors from affecting company matters.

Future Outlook

The company expects to continue to incur significant operating losses for the foreseeable future as it continues the development of its diagnostic tests and advances its diagnostic tests through clinical trials. The company anticipates raising additional cash needed through the private or public sales of equity or debt securities, collaborative arrangements, or a combination thereof to continue to fund its operations and develop its products.

Management Comments

• Dr. Downie opined that adding CyPath Lung to our algorithm has accelerated diagnosis, helped guide difficult clinical discussions, and prevented unnecessary invasive procedures.

Industry Context

The company operates in the diagnostic testing and cancer therapeutics industry, which is characterized by rapid innovation and intense competition. The company's focus on noninvasive early-stage lung cancer detection aligns with the growing trend towards personalized medicine and early intervention.

Comparison to Industry Standards

• It is difficult to compare bioAffinity's results directly to industry standards due to its unique focus and stage of development.
• Comparable companies in the diagnostic testing space include Exact Sciences (EXAS) and Guardant Health (GH), but these companies have a broader range of products and are at a different scale.
• bioAffinity's CyPath Lung test competes with other lung cancer screening methods, such as low-dose CT scans, but offers a noninvasive alternative.
• The company's therapeutic discoveries are in early stages and cannot be directly compared to established cancer treatments.

Stakeholder Impact

• Shareholders face the risk of further dilution and potential loss of investment.
• Employees may be affected by cost-saving measures and potential restructuring.
• Customers may benefit from the company's focus on CyPath Lung and improved diagnostic accuracy.
• Suppliers and creditors face increased risk due to the company's financial challenges.

Next Steps

• The company intends to seek strategic partners to develop its therapeutic discoveries.
• The company intends to actively monitor the bid price of its Common Stock and will consider available options to regain compliance with the Nasdaq listing requirements.
• The company will continue to seek sources of financing to fund its continued operations and research and development programs.

Key Dates

Keywords

bioAffinity Technologies, CyPath Lung, revenue, net loss, clinical trials, diagnostic tests, financial results, going concern, capital raise, warrants, 10-Q